Antonio Carlesso

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 7

Top Topics

Molecular Docking

Tyrosine Kinase

Induced Pluripotent Stem Cells

Top Venues

Communications chemistry

Scientific reports

The FEBS journal

This page only lists publications with an associated author ORCID identifier.

Publications

S Jalil Mahdizadeh, Johan Grandén, Diana Pelizzari-Raymundo, Xavier Guillory, Antonio Carlesso, Éric Chevet, Leif A Eriksson
Different binding modalities of quercetin to inositol-requiring enzyme 1 of S. cerevisiae and human lead to opposite regulation. Communications chemistry 7 (1) (2024)
S Jalil Mahdizadeh, Johan Grandén, Diana Pelizzari-Raymundo, Xavier Guillory, Antonio Carlesso, Éric Chevet, Leif A Eriksson
Different binding modalities of quercetin to inositol-requiring enzyme 1 of S. cerevisiae and human lead to opposite regulation. Communications chemistry 7 (1) (2024)
S Jalil Mahdizadeh, Johan Grandén, Diana Pelizzari-Raymundo, Xavier Guillory, Antonio Carlesso, Éric Chevet, Leif A Eriksson
Different binding modalities of quercetin to inositol-requiring enzyme 1 of S. cerevisiae and human lead to opposite regulation. Communications chemistry 7 (1) (2024)
Chetan Chintha, Antonio Carlesso, Adrienne M Gorman, Afshin Samali, Leif A Eriksson
Molecular modeling provides a structural basis for PERK inhibitor selectivity towards RIPK1. RSC advances 10 (1) (2020)
Sayyed Jalil Mahdizadeh, Antonio Carlesso, Leif A Eriksson
Deciphering the selectivity of inhibitor MKC9989 towards residue K907 in IRE1α; a multiscale in silico approach. RSC advances 10 (33) (2020)
Antonio Carlesso, Johanna Hörberg, Anna Reymer, Leif A Eriksson
New insights on human IRE1 tetramer structures based on molecular modeling. Scientific reports 10 (1) (2020)
Dimitrios Doultsinos, Antonio Carlesso, Chetan Chintha, James C Paton, Adrienne W Paton, Afshin Samali, Éric Chevet, Leif A Eriksson
Peptidomimetic-based identification of FDA-approved compounds inhibiting IRE1 activity. The FEBS journal 288 (3) (2020)